The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects

Albaugh, BJ, Anderson, PO (1974) Peyote in the treatment of alcoholism among American Indians. Am J Psychiatry 131: 1247–1250.
Google Scholar | Crossref | Medline | ISI Ashrafioun, L, Bonadio, FA, Baik, KD, et al. (2016) Patterns of use, acute subjective experiences, and motivations for using synthetic cathinones (“bath salts”) in recreational users. J Psychoactive Drugs 48: 336–343.
Google Scholar | Crossref | Medline Barrett, FS, Bradstreet, MP, Leoutsakos, J-MS, et al. (2016) The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. J Psychopharmacol 30: 1279–1295.
Google Scholar | SAGE Journals | ISI Barrett, FS, Johnson, MW, Griffiths, RR (2015) Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J Psychopharmacol 29: 1182–1190.
Google Scholar | SAGE Journals | ISI Bevan, P, Bradshaw, C, Roberts, M, et al. (1974) The effect of microelectrophoretically applied mescaline on cortical neurones. Neuropharmacology 13: 1033–1045.
Google Scholar | Crossref | Medline Beyerstein, BL (2003) Hallucinogens: A Forensic Handbook. Academic Press.
Google Scholar Carhart-Harris, RL, Bolstridge, M, Rucker, J, et al. (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3: 619–627.
Google Scholar | Crossref | Medline | ISI Carstairs, SD, Cantrell, FL (2010) Peyote and mescaline exposures: A 12-year review of a statewide poison center database. Clin Toxicol 48: 350–353.
Google Scholar | Crossref Cattell, JP (1954) The influence of mescaline on psychodynamic material. J Nerv Ment Dis 119: 233–244.
Google Scholar | Crossref | Medline Clarke, PB, Giordano, AL, Cashwell, CS, et al. (2013) The straight path to healing: Using motivational interviewing to address spiritual bypass. J Couns Dev 91: 87–94.
Google Scholar | Crossref Cochin, J, Woods, L, Seevers, M (1951) The absorption, distribution and urinary excretion of mescaline in the dog. J Pharmacol Exp Ther 101: 205–209.
Google Scholar | Medline Cohen, S (1960) Lysergic acid diethylamide: Side effects and complications. J Nerv Ment Dis 130: 30–40.
Google Scholar | Crossref | Medline | ISI Darvesh, AS, Gudelsky, GA (2003) Activation of 5-HT2 receptors induces glycogenolysis in the rat brain. Eur J Pharmacol 464: 135–140.
Google Scholar | Crossref | Medline Dasgupta, A (2019) Abuse of Magic Mushroom, Peyote Cactus, LSD, Khat, and Volatiles. In: Critical Issues in Alcohol and Drugs of Abuse Testing. Elsevier, pp.477–494.
Google Scholar | Crossref Davis, AK, Barrett, FS, Griffiths, RR (2020a) Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. J Contextual Behav Sci 15: 39–45.
Google Scholar | Crossref | Medline Davis, AK, Barrett, FS, May, DG, et al. (2020b) Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry e203285.
Google Scholar Davis, AK, Barrett, FS, So, S, et al. (2021) Development of the psychological insight questionnaire among a sample of people who have consumed psilocybin or LSD. J Psychopharmacol. Epub ahead of print 9 January 2021. DOI: 10.1177/0269881120967878.
Google Scholar | SAGE Journals Davis, AK, Barsuglia, JP, Lancelotta, R, et al. (2018) The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. J Psychopharmacol 32: 779–792.
Google Scholar | SAGE Journals | ISI Davis, AK, So, S, Lancelotta, R, et al. (2019) 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. Am J Drug Alcohol Abuse 45: 161–169.
Google Scholar | Crossref | Medline Delgado, PL, Moreno, FA (1998) Hallucinogens, serotonin and obsessive-compulsive disorder. J Psychoactive Drugs 30: 359–366.
Google Scholar | Crossref | Medline Dobkin, M (1968) Trichocereus pachanoi—A mescaline cactus used in folk healing in Peru. Econ Bot 22: 191–194.
Google Scholar Drug Enforcement Administration (DEA) (2019) Drug Enforcement Administration, Department of Justice. Controlled Substances in Alphabetical Order. Available at: https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf.
Google Scholar Dunnell, T (2018) Drugs in Peru: The Laws of Legal and Illegal Possession. Available at: www.newperuvian.com/drugs-in-peru-legal-and-illegal/ (accessed 19 October 2018).
Google Scholar Epstein, K (2019) Oakland decriminalizes ‘magic mushrooms’ and other natural psychedelics. The Washington Post, 6 June, 2019.
Google Scholar Erowid (2009) The Flesh of God: Peyote and CannabisPeyote (exp55601). Avaliable at: www.erowid.org/exp/55601.
Google Scholar Erowid (2011) A Seminal Spiritual Event: An Experience with Mescaline (exp91450). Available at: www.erowid.org/exp/91450.
Google Scholar Erowid (2012) WhoAreYou. Accepting Death and Utter Ecstasy: An Experience with Mescaline (exp88982). Available at: https://erowid.org/experiences/exp.php?ID=88982.
Google Scholar Fox, J, Cashwell, CS, Picciotto, G (2017) The opiate of the masses: Measuring spiritual bypass and its relationship to spirituality, religion, mindfulness, psychological distress, and personality. Spiritual Clin Pract 4: 274.
Google Scholar | Crossref Frederking, W (1955) Intoxicant drugs (mescaline and lysergic acid diethylamide) in psychotherapy. J Nerv Ment Dis 121: 262–266.
Google Scholar | Crossref | Medline Garcia-Romeu, A, Davis, AK, Erowid, F, et al. (2019) Cessation and reduction in alcohol consumption and misuse after psychedelic use. J Psychopharmacol 33: 1088–1101.
Google Scholar | SAGE Journals | ISI Garcia-Romeu, A, Davis, AK, Erowid, E, et al. (2020) Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey. Front Psychiatry 10: 955.
Google Scholar | Crossref | Medline Garcia-Romeu, A, Kersgaard, B, Addy, PH (2016) Clinical applications of hallucinogens: A review. Exp Clin Psychopharmacol 24: 229.
Google Scholar | Crossref | Medline | ISI Griffiths, RR, Johnson, MW, Richards, WA, et al. (2011) Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology 218: 649–665.
Google Scholar | Crossref | Medline | ISI Griffiths, RR, Richards, WA, McCann, U, et al. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187: 268–283.
Google Scholar | Crossref | Medline | ISI Guttmann, E (1936) Artificial psychoses produced by mescaline. J Ment Sci 82: 203–221.
Google Scholar | Crossref Halpern, JH, Sherwood, AR, Hudson, JI, et al. (2005) Psychological and cognitive effects of long-term peyote use among Native Americans. Biol Psychiatry 58: 624–631.
Google Scholar | Crossref | Medline | ISI Halpern, S (1961) On the similarity between hypnotic and mescaline hallucinations. Int J Clin Exp Hypn 9: 139–149.
Google Scholar | Crossref | Medline Hartogsohn, I (2017) Constructing drug effects: a history of set and setting. Drug Sci Policy Law 3: 2050324516683325.
Google Scholar | SAGE Journals Hermle, L, Fünfgeld, M, Oepen, G, et al. (1992) Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Biol Psychiatry 32: 976–991.
Google Scholar | Crossref | Medline | ISI Jay, M (2019) Mescaline: A Global History of the First Psychedelic: Yale University Press.
Google Scholar | Crossref Johansen, P-Ø, Krebs, TS (2015) Psychedelics not linked to mental health problems or suicidal behavior: A population study. J Psychopharmacol 29: 270–279.
Google Scholar | SAGE Journals | ISI Johnson, MW, Garcia-Romeu, A, Cosimano, MP, et al. (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 0269881114548296.
Google Scholar Kapadia, GJ, Fayez, M (1970) Peyote constituents: Chemistry, biogenesis, and biological effects. J Pharm Sci 59: 1699–1727.
Google Scholar | Crossref | Medline Klüver, H (1926) Mescal visions and eidetic vision. Am J Psychol 37: 502–515.
Google Scholar | Crossref Knauer, A, Maloney, W (1913) A preliminary note on the psychic action of mescaline, with special reference to the mechanism of visual hallucinations. J Nerv Ment Dis 40: 425.
Google Scholar | Crossref Koelle, GB (1958) The pharmacology of mescaline and D-lysergic acid diethylamide (LSD). N Engl J Med 258: 25–32.
Google Scholar | Crossref | Medline Krebs, TS, Johansen, P-Ø (2013) Psychedelics and mental health: A population study. PLoS One 8: e63972.
Google Scholar | Crossref | Medline | ISI Kyzar, EJ, Collins, C, Gaikwad, S, et al. (2012) Effects of hallucinogenic agents mescaline and phencyclidine on zebrafish behavior and physiology. Prog Neuropsychopharmacol Biol Psychiatry 37: 194–202.
Google Scholar | Crossref | Medline | ISI Luke, D, Terhune, DB (2013) The induction of synaesthesia with chemical agents: A systematic review. Front Psychol 4: 753.
Google Scholar | Crossref | Medline McCabe, SE, West, BT, Jutkiewicz, EM, et al. (2017) Multiple DSM-5 substance use disorders: A national study of US adults. Hum Psychopharmacol 32: e2625.
Google Scholar | Crossref McLaughlin, JL (1973) Peyote: an introduction. Lloydia 36: 1–8.
Google Scholar | Medline MacLean, KA, Johnson, MW, Griffiths, RR (2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol 25: 1453–1461.
Google Scholar | SAGE Journals | ISI Mason, NL, Mischler, E, Uthaug, MV, et al. (2019) Sub-acute effects of psilocybin on empathy, creative thinking, and subjective well-being. J Psychoactive Drugs 1–12.
Google Scholar Monte, AP, Waldman, SR, Marona-Lewicka, D, et al. (1997) Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives. J Med Chem 40: 2997–3008.
Google Scholar | Crossref | Medline Nichols, DE (2004) Hallucinogens. Pharmacol Therapeut 101: 131–181.
Google Scholar | Crossref | Medline | ISI Nichols, DE (2016) Psychedelics. Pharmacol Rev 68: 264–355.
Google Scholar | Crossref | Medline | ISI Nolte, KB, Zumwalt, RE (1999) Fatal peyote ingestion associated with Mallory-Weiss lacerations. West J Med 170: 328.
Google Scholar | Medline

留言 (0)

沒有登入
gif